119 related articles for article (PubMed ID: 17710191)
1. Evaluation of the Oral Bioavailability of Low Molecular Weight Heparin Formulated With Glycyrrhetinic Acid as Permeation Enhancer.
Motlekar NA; Srivenugopal KS; Wachtel MS; Youan BB
Drug Dev Res; 2006 Feb; 67(2):166-174. PubMed ID: 17710191
[TBL] [Abstract][Full Text] [Related]
2. Zonula occludens toxin synthetic peptide derivative AT1002 enhances in vitro and in vivo intestinal absorption of low molecular weight heparin.
Motlekar NA; Fasano A; Wachtel MS; Youan BB
J Drug Target; 2006 Jun; 14(5):321-9. PubMed ID: 16882552
[TBL] [Abstract][Full Text] [Related]
3. Modulation of gastrointestinal permeability of low-molecular-weight heparin by L-arginine: in-vivo and in-vitro evaluation.
Motlekar NA; Srivenugopal KS; Wachtel MS; Youan BB
J Pharm Pharmacol; 2006 May; 58(5):591-8. PubMed ID: 16640827
[TBL] [Abstract][Full Text] [Related]
4. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels.
Motlekar NA; Srivenugopal KS; Wachtel MS; Youan BB
J Drug Target; 2005 Dec; 13(10):573-83. PubMed ID: 16390818
[TBL] [Abstract][Full Text] [Related]
5. N-sulfonato-N,O-carboxymethylchitosan: a novel polymeric absorption enhancer for the oral delivery of macromolecules.
Thanou M; Henderson S; Kydonieus A; Elson C
J Control Release; 2007 Feb; 117(2):171-8. PubMed ID: 17184870
[TBL] [Abstract][Full Text] [Related]
6. Tetradecylmaltoside (TDM) enhances in vitro and in vivo intestinal absorption of enoxaparin, a low molecular weight heparin.
Yang T; Arnold JJ; Ahsan F
J Drug Target; 2005 Jan; 13(1):29-38. PubMed ID: 15848952
[TBL] [Abstract][Full Text] [Related]
7. Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system.
Schmitz T; Leitner VM; Bernkop-Schnürch A
J Pharm Sci; 2005 May; 94(5):966-73. PubMed ID: 15793802
[TBL] [Abstract][Full Text] [Related]
8. Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin.
Troy S; Fruncillo R; Ozawa T; Mammen E; Holloway S; Chiang S
Thromb Haemost; 1997 Aug; 78(2):871-5. PubMed ID: 9268187
[TBL] [Abstract][Full Text] [Related]
9. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation.
Kim SK; Vaishali B; Lee E; Lee S; Lee YK; Kumar TS; Moon HT; Byun Y
Thromb Res; 2006; 117(4):419-27. PubMed ID: 15913716
[TBL] [Abstract][Full Text] [Related]
10. Bioactive self-assembling lipid-like peptides as permeation enhancers for oral drug delivery.
Karavasili C; Spanakis M; Papagiannopoulou D; Vizirianakis IS; Fatouros DG; Koutsopoulos S
J Pharm Sci; 2015 Jul; 104(7):2304-11. PubMed ID: 25994901
[TBL] [Abstract][Full Text] [Related]
11. Nasal administration of low molecular weight heparin.
Arnold J; Ahsan F; Meezan E; Pillion DJ
J Pharm Sci; 2002 Jul; 91(7):1707-14. PubMed ID: 12115833
[TBL] [Abstract][Full Text] [Related]
12. pH-responsive thiolated chitosan nanoparticles for oral low-molecular weight heparin delivery: in vitro and in vivo evaluation.
Fan B; Xing Y; Zheng Y; Sun C; Liang G
Drug Deliv; 2016; 23(1):238-47. PubMed ID: 24865290
[TBL] [Abstract][Full Text] [Related]
13. A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine.
Gupta V; Hwang BH; Doshi N; Mitragotri S
J Control Release; 2013 Dec; 172(2):541-9. PubMed ID: 23680288
[TBL] [Abstract][Full Text] [Related]
14. The disposition of diammonium glycyrrhizinate and glycyrrhetinic acid in the isolated perfused rat intestine and liver.
Yang J; Zhou L; Wang J; Wang G; Davey AK
Planta Med; 2008 Sep; 74(11):1351-6. PubMed ID: 18671195
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Lim KM; Moon HT; Kim CY; Byun Y
Thromb Haemost; 2011 Jun; 105(6):1060-71. PubMed ID: 21437357
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group.
Heit JA; Berkowitz SD; Bona R; Cabanas V; Corson JD; Elliott CG; Lyons R
Thromb Haemost; 1997 Jan; 77(1):32-8. PubMed ID: 9031445
[TBL] [Abstract][Full Text] [Related]
17. Preparation and evaluation of a novel oral delivery system for low molecular weight heparin.
Lavanya N; Muzib YI; Aukunuru J; Balekari U
Int J Pharm Investig; 2016; 6(3):148-57. PubMed ID: 27606258
[TBL] [Abstract][Full Text] [Related]
18. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
Kim SK; Lee DY; Lee E; Lee YK; Kim CY; Moon HT; Byun Y
J Control Release; 2007 Jul; 120(1-2):4-10. PubMed ID: 17490773
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
[TBL] [Abstract][Full Text] [Related]
20. The dose proportionality of the pharmacokinetics of ardeparin, a low molecular weight heparin, in healthy volunteers.
Troy S; Fruncillo R; Ozawa T; Mammen E; Holloway S; Chiang S
J Clin Pharmacol; 1995 Dec; 35(12):1194-9. PubMed ID: 8750371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
